BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38329413)

  • 21. Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis.
    Williamson SR; Gupta NS; Eble JN; Rogers CG; Michalowski S; Zhang S; Wang M; Grignon DJ; Cheng L
    Am J Surg Pathol; 2015 Nov; 39(11):1502-10. PubMed ID: 26457355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.
    Sarungbam J; Mehra R; Tomlins SA; Smith SC; Jayakumaran G; Al-Ahmadie H; Gopalan A; Sirintrapun SJ; Fine SW; Zhang Y; Amin MB; Reuter VE; Chen YB; Tickoo SK
    Mod Pathol; 2019 May; 32(5):701-709. PubMed ID: 30622286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists' ever-expanding differential diagnosis for a heterogeneous group of entities.
    Taylor AS; Skala SL
    Urol Oncol; 2022 Dec; 40(12):499-511. PubMed ID: 34116938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
    Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
    Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cascade Fumarate Hydratase mutation screening allows early detection of kidney tumour: a case report.
    Chan MMY; Barnicoat A; Mumtaz F; Aitchison M; Side L; Brittain H; Bates AWH; Gale DP
    BMC Med Genet; 2017 Jul; 18(1):79. PubMed ID: 28747166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hereditary kidney cancers: The pathologist's view in 2020].
    Verkarre V; Morini A; Denize T; Ferlicot S; Richard S
    Ann Pathol; 2020 Apr; 40(2):148-167. PubMed ID: 32197858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
    Chen YB
    Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Intact FH Staining Sufficient to Rule out the Possibility of FH-Deficient Renal Cell Carcinoma?
    Hamza Md A
    Int J Surg Pathol; 2023 Aug; 31(5):907-908. PubMed ID: 35775107
    [No Abstract]   [Full Text] [Related]  

  • 29. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
    Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
    J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
    Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
    Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis.
    Saleeb RM; Brimo F; Farag M; Rompré-Brodeur A; Rotondo F; Beharry V; Wala S; Plant P; Downes MR; Pace K; Evans A; Bjarnason G; Bartlett JMS; Yousef GM
    Am J Surg Pathol; 2017 Dec; 41(12):1618-1629. PubMed ID: 28984673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications.
    Kanakaraj J; Chang J; Hampton LJ; Smith SC
    Urol Oncol; 2024 Jul; 42(7):211-219. PubMed ID: 38519377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.
    Merino MJ; Torres-Cabala C; Pinto P; Linehan WM
    Am J Surg Pathol; 2007 Oct; 31(10):1578-85. PubMed ID: 17895761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
    Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
    Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
    Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
    Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights in the new WHO classification of adult renal tumors.
    Hes O; Michalová K; Pivovarčíková K
    Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How New Developments Impact Diagnosis in Existing Renal Neoplasms.
    Akgul M; Williamson SR
    Surg Pathol Clin; 2022 Dec; 15(4):695-711. PubMed ID: 36344184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
    Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
    Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
    Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
    Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.